ClinicalTrials.gg
RecruitingNCT07473323Updated Jun 29, 2026

Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

A Phase 1 interventional study of MTX-439 and Placebo in Healthy Adult Participants and Diabetic Kidney Disease, sponsored by Mediar Therapeutics. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Diabetic Nephropathies with a site in Australia — 2 open to participants now, 4 under way, 1 of them phase 3. Diabetic Nephropathies · Australia.

Planned enrollment
20th of 26
88 · median 246
Started
2026
the only one that year
Phase 1
Only one
of the 27
Registered
27th of 27
by date

Among the 27 studies in Diabetic Nephropathies with a site in Australia, this one is the 20th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1, and was the 27th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

2 of the 27 studies in Diabetic Nephropathies with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diabetic Nephropathies with a site in Australia, or all of them as a file.
02

Study summary

This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439 administered in healthy adults and adults with diabetic kidney disease (DKD)

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to assess the safety, tolerability, and PK of single- and multiple-ascending doses of MTX-439 administered in healthy adults and adults with DKD.

The SAD portion of the study with healthy participants will consist of 5 planned intravenous (IV) dosing cohorts, comprising 8 participants. Dosing will be weight based, and the starting dose will be 100 fold below the top of the safety window. Doses will then be increased, depending on the safety, tolerability and drug exposure levels, in subsequent Cohorts, with increases proceeding in either 2x or 3x increments. . Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data. Within each HP cohort, participants will be randomly assigned to receive MTX-439 or matched placebo. The first 2 participants (sentinel participants) within each HP cohort will be randomized 1:1 to receive MTX-439 or placebo on Day 1. These participants will be monitored for 24 hours and, after review of the safety data from both participants and approval by the study Investigator, Medical Monitor, and Sponsor's Responsible Medical Officer (SRMO), the additional 6 participants will be randomized to study drug (n=5 MTX-439; n=1 placebo).

In addition, a minimum of 2 planned IV dosing cohorts comprising 8 DKD participants will receive MTX439 or matched placebo to assess the PK in patients vs healthy controls. DKD Cohort 1 may be dosed any time after the dose escalation meeting for HP Cohort 2 is completed, and the decision is made to dose escalate. The starting dose of study drug in DKD Cohort 1 will be the same as the dose for Cohort 1 in healthy volunteers. No dose can be administered to DKD participants until the same or higher dose has been safely administered to healthy participants. Participants in the DKD SAD portion of the study will be randomized 3:1 to receive MTX-439 or matched placebo on Day 1. Sentinel dosing will not be required in DKD cohorts.

The MAD portion of the study will consist of 4 planned IV dosing cohorts comprising 8 healthy participants (n=6 MTX-439; n=2 placebo).Dosing for each MAD cohort is planned for Day 1, Day 15 and Day 29. Cohort 1 of the MAD portion of the study can begin following completion of the SAD Cohort 2 safety meeting and once the study Investigator, Medical Monitor, and SRMO decide to proceed to HP SAD Cohort 3. Dose escalation will occur depending on the safety, tolerability and PK in previous cohorts.

Participants will be in the study will be followed for safety and be assessed for PK and immunogenicity. For SAD cohorts, participation will be 85 days and for MAD cohorts 113 days.

03

Conditions studied

  • Healthy Adult Participants
  • Diabetic Kidney Disease

Keywords

  • MTX-439-K101
  • MTX-439
  • Healthy Volunteers
  • Diabetic Kidney Disease
  • HV
  • DKD
  • Adult
  • Monoclonal Antibody
  • SMOC2
  • SAD
  • MAD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All genders, ages 18 to 65 years, inclusive.
  2. Able to read and understand the study and all related materials (including the ICF), and provide a signed, written .
  3. Willing and able to complete all protocol-required study visits and procedures.
  4. Consumption of no more than 5 cigarettes or other cotinine-containing products (including tobacco, nicotine gum, patches, nicotine pouches, and e-cigarettes) per week and agreement to abstain from all such products during inpatient stays.
  5. Willing to refrain from marijuana- or cannabinol-containing products for 30 days before Screening and until the last study visit.
  6. Agrees to not donate eggs (if applicable) from the time of the first infusion until 65 days after the final dose, or 125 days after the final dose for sperm (if applicable); additionally agrees to not donate blood from 56 days prior to the time of first infusion until 90 days after the last study visit or /plasma from 14 days prior to the time of first infusion until 90 days after the last study visit.
  7. Participants are required to follow specific measures as follows:

    • Participants assigned male at birth must use a condom (even if vasectomised) at the time of Screening and for 125 days after the final dose.
    • Participants assigned female at birth must be of nonchildbearing potential (defined as either at least 6 months surgically sterilised or at least 1 year and confirmed by follicle-stimulating hormone [FSH] level > 40 U/L) OR, if of (defined as not sterilised via bilateral oophorectomy or hysterectomy; still menstruating; or \< 1 year has passed since the last menses, if menopausal), must use a combination of 1 highly effective method of contraception and 1 effective method of contraception. This contraceptive practice should begin at least 28 days before the first dose of study drug, continue during the study, and persist for 65 days after the final dose of study drug, if applicable.
    • Male participants agree to ensure that their female partners who are of childbearing potential will use a highly effective method of contraception..
  8. Vital signs within the following ranges:

    • Systolic blood pressure: 90-140 mmHg
    • Diastolic blood pressure: \< 90 mmHg
    • Pulse rate: 55-100 bpm
    • Respiration rate: 10-16 respirations per minute

    DKD participants:

  9. All of the above.

    • Well-controlled diabetes requiring minimal dose adjustments of antidiabetic medications in the past 3 months and no adjustments within 30 days of Screening.
    • \< 9.5%.
    • Estimated (eGFR) between 30 and 60.

Exclusion criteria

Exclusion Criteria:

  1. Any active medical condition determined by the Investigator, except for DKD (for DKD participants).
  2. (BMI) > 32 kg/m2 for healthy participants; > 40 kg/m2 for DKD participants.
  3. Use of any systemic medications, medications to treat diabetes (except DKD participants), antipsychotics, anticoagulants, or other prescription medications other than within 90 days of Screening that, as determined by the Investigator, could confound their participation in the study.
  4. Received a vaccine within 30 days of Screening.
  5. Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening except for adequately treated non-melanoma cancers of the skin and cervical carcinoma in situ.
  6. Current infection with , , or (HIV) as evidenced by a positive hepatitis B surface antigen (HbsAg) test at Screening or a positive HIV test at Screening. For hepatitis C, a positive hepatitis C antibody (antiHCV) test is exclusionary unless the participant has previously been treated for hepatitis C, in which case they would be eligible with a negative HCV ribonucleic (RNA) test.
  7. Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 65 days (for participants of ) or 125 days (for males) after the participant's last dose of study drug, if applicable.
  8. History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 5 years of Screening.
  9. History of anaphylaxis or other significant allergies in the opinion of the Investigator.
  10. History of substance use disorder as specified in , Fifth Edition, within 1 year of Screening.
  11. Positive screen for drugs of abuse or alcohol at Screening or admission to the CRU (Day -1).
  12. Donation of blood within 28 days of Screening.
  13. Any clinically significant disease or laboratory abnormality detected at Screening, including diabetes mellitus, that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety, including the following:

    • \< 115 g/L (female) or \< 135 g/L (male); > 160 g/L (female) or > 180 g/L (male)
    • Absolute neutrophils \< 2.0 × 109/L or > 7.5 × 109/L
    • White blood cells \< 4.0 × 109/L or > 11.0 × 109/L
    • count \< 150 × 109/L or > 450 × 109/L
    • Any clinically significant abnormality on any of the Screening ECGs
    • or aspartate aminotransferase greater than 1.2 times the .
  14. Any surgical procedure, including planned procedures within 12 weeks of Screening.
  15. Known allergy to MTX-439 or any of its .
  16. Participation in another research study of an agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    MTX-439

    MTX-439

    Biological: MTX-439

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalMTX-439

    MTX-439 is a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds human-secreted protein SMOC2 with high specificity and high affinity

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Number and percentage of participants who experience a dose-limiting toxicity (DLT) as defined in the protocol. Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of participants with at least one treatment-emergent adverse event (TEAE). TEAEs will be summarized by seriousness and maximum severity according to protocol-defined criteria Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  3. Incidence of Treatment-Related Adverse Events (TRAEs)

    Number and percentage of participants with at least one adverse event considered related to study intervention by the investigator. Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  4. Incidence of Dose Modifications Due to Adverse Events

    Number and percentage of participants requiring dose interruption, dose reduction, or permanent discontinuation of study intervention due to adverse events. Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  5. Clinically Significant Changes in Physical Examination Findings

    Number and percentage of participants with clinically significant abnormalities in physical examination findings. Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  6. Clinically Significant Changes in Vital Signs

    Number and percentage of participants with clinically significant changes from baseline in vital signs measurements (including blood pressure, heart rate, respiratory rate, temperature, and pulse oximetry). Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  7. Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Number and percentage of participants with clinically significant abnormalities in ECG parameters (including but not limited to PR interval, QRS duration, and QT/QTc interval). Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  8. Clinically Significant Changes in Clinical Laboratory Parameters

    Number and percentage of participants with clinically significant changes from baseline in hematology, clinical chemistry, urinalysis, and other protocol-specified laboratory parameters. Unit of Measure: Number of participants; Percentage of participants (%)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  9. Maximum Observed Plasma Concentration (Cmax) of MTX-439

    Maximum observed plasma concentration (Cmax) of MTX-439 following single and multiple ascending doses. Unit of Measure: Nanograms per milliliter (ng/mL)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  10. Area Under the Plasma Concentration-Time Curve From Time Zero to Time t (AUC0-t) of MTX-439

    Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of MTX-439. Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  11. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of MTX-439

    Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of MTX-439. Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  12. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of MTX-439

    Area under the plasma concentration-time curve over the dosing interval (AUC0-tau) of MTX-439 at steady state, where applicable Unit of Measure: Nanogram·hour per milliliter (ng·h/mL)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  13. Time to Maximum Plasma Concentration (Tmax) of MTX-439

    Time to reach maximum observed plasma concentration (Tmax) of MTX-439 following dosing. Unit of Measure: Hours (h)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  14. Terminal Elimination Half-Life (t1/2) of MTX-439

    Terminal elimination half-life (t1/2) of MTX-439 following dosing. Unit of Measure: Hours (h)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  15. Incidence and Characterization of Anti-Drug Antibodies (ADA)

    Number and percentage of participants with detectable anti-drug antibodies (ADA), including ADA titer and assessment of the impact of ADA on PK and safety, if applicable. Unit of Measure: Number of participants; Percentage of participants (%); Titer (unitless dilution factor)

    Time frame: From first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

Secondary outcomes

  1. Change From Baseline in Total SMOC2 Levels

    Change from Baseline in circulating total SMOC2 levels following administration of MTX-439 Unit of Measure: Nanograms per milliliter (ng/mL)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  2. Change From Baseline in Free SMOC2 Levels

    Change from Baseline in circulating free SMOC2 levels following administration of MTX-439. Unit of Measure: Nanograms per milliliter (ng/mL)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

Other outcomes

  1. Change From Baseline in Pro-inflammatory Biomarkers

    Change from Baseline in circulating pro-inflammatory biomarkers following administration of MTX-439. Unit of Measure: Nanograms per milliliter (ng/mL)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

  2. Change From Baseline in Fibrosis Biomarkers

    Change from Baseline in fibrosis biomarkers, including fragment of PRO-C3, PRO-C6, and collagen VII metabolite (C7M), following administration of MTX-439. Unit of Measure: Nanograms per milliliter (ng/mL)

    Time frame: Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

07

Study locations

1 of 1 sites recruiting
  • Doherty Clinical Trials
    Melbourne, Victoria 3002, Australia
    Recruiting
    • Julia Marshall, MD · Contact+61 03 9970 4200
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 20 phase 1 interventional studies under Diabetic Nephropathies, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 16, 2026
StartActual
May 19, 2026
Primary completionEst.
May 2027
CompletionEst.
Jan 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07473323
Lead sponsor
Mediar Therapeutics
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
May 19, 2026
Primary completion
May 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Jeffrey Bornstein, MD
Contact
jeffrey@mediartx.com
(617) 936-0960 ext. 803
Jordan Jara
Contact
jordan.jara@mediartx.com
617-936-0960 ext. 818

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion